**Table 1. Characteristics of herpes zoster cases reported with mRNA COVID-19 vaccines in the WHO global safety database**

|  |  |  |  |
| --- | --- | --- | --- |
| **Reporting characteristics** | **BNT162b2 (n=5931)** | **mRNA-1273 (n=1797)** | **Overall**  **(n=7728)** |
| Continent of reporting  Africa  Asia-Oceania  Europe  North America  South America | 13 (0.2%)  112 (1.9%)  3616 (61.0%)  2173 (36.6%)  17 (0.3%) | -  1 (0.1%)  358 (19.9%)  1438 (80.0%)  - | 13 (0.2%)  113 (1.5%)  3974 (51.4%)  3611 (46.7%)  17 (0.2%) |
| Type of reporter  Pharmacist  Physician  Other health professional  Consumer  Unknown | 162 (2.7%)  1431 (24.1%)  252 (4.2%)  1869 (32.5%)  2217 (37.4%) | 19 (1.1%)  192 (10.7%)  5 (0.3%)  144 (8.0%)  1437 (80.0%) | 181 (2.3%)  1623 (21.0%)  257 (3.3%)  2013 (26.0%)  3654 (47.3%) |
| Sex – female | 3903 (65.8%) | 1232 (68.6%) | 5135 (66.4%) |
| Age – years | 59.7 (46-73) | 57.0 (44-70) | 59.1 (46-72) |
| Age – ranges  < 12 years  12 - 17 years  18 - 39 years  40 - 64 years  65 - 74 years  ≥ 75 years  Unknown | 10 (0.2%)  13 (0.2%)  831 (14.0%)  2230 (37.6%)  1188 (20.0%)  1200 (20.2%)  459 (7.7%) | -  1 (0.1%)  312 (17.4%)  780 (43.4%)  374 (20.8%)  288 (16.0%)  42 (2.3%) | 10 (0.1%)  14 (0.2%)  1143 (14.8%)  3010 (38.9%)  1562 (20.2%)  1488 (19.3%)  501 (6.5%) |
| Type of injury: skin rash\*  Age - years  Time to reaction onset – days  Requiring hospitalization | 5733 (96.6%)  61 (46-73)  7 (2-14)  131 (2.3%) | 1761 (98.0%)  57 (44-70)  7 (2-16)  42 (2.4%) | 7494 (97.0%)  60 (45-72)  7 (2-15)  173 (2.3%) |
| Type of injury: ophtalmicus  Age - years  Time to reaction onset – days  Requiring hospitalization | 165 (2.8%)  68 (56-78)  8 (2.75-15)  21 (12.7%) | 32 (1.8%)  69 (56.5-75.5)  4 (2-13.8)  2 (6.0%) | 197 (2.5%)  68 (56-77.5)  7 (2-14.75)  23 (11.7%) |
| Type of injury: oticus  Age - years  Time to reaction onset – days  Requiring hospitalization | 47 (0.8%)  57 (44.5-66.5)  5 (2-12)  6 (12.8%) | 13 (0.7%)  47 (40-59)  3 (1-11)  - | 60 (0.8%)  57 (41.75-66.25)  4 (1.75-11.75)  6 (10%) |
| Type of injury: central nervous system  *Meningitis*  *Meningoencephalitis*  *Meningoradiculitis*  *Unspecified neurological infection*  Age - years  Time to reaction onset – days  Requiring hospitalization | 19 (0.3%)  *9 (47.4%)*  *5 (26.3%)*  *2 (10.5%)*  *3 (15.8%)*  65 (55-78)  18 (2.5-30)  11 (57.9%) | 6 (0.3%)  *3 (50%)*  *2 (33.3%)*  *-*  *1 (16.7%)*  47.5 (33-72.5)  17 (13-21)  3 (50%) | 25 (0.3%)  *12 (48%)*  *7 (28%)*  *2 (8%)*  *4 (16%)*  65 (47-77)  17.5 (12.5-29)  14 (56%) |
| Cases with another suspected reported drug | 45 (0.8%) | 17 (0.9%) | 62 (0.8%) |
| Month of reporting  December  January  February  March  April  May  June | 5 (0.1%)  151 (2.5%)  370 (6.2%)  542 (9.1%)  728 (12.3%)  1680 (28.3%)  2455 (41.4%) | 0  5 (0.3%)  24 (1.3%)  86 (4.8%)  129 (7.2%)  660 (36.7%)  893 (46.7%) | 5 (0.1%)  156 (2.0%)  394 (5.1%)  628 (8.1%)  857 (11.1%)  2340 (30.3%)  3348 (43.3%) |

*Footnote:* Data are presented as N (%) or median (IQR)

As patients could develop more than one type of lesion, the number of type of injury exceed the number of cases

\* including seven genital injuries for BNT162b2 and none for mRNA-1273.